Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
GCTK
Upturn stock ratingUpturn stock rating

GlucoTrack Inc (GCTK)

Upturn stock ratingUpturn stock rating
$7.55
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

09/17/2025: GCTK (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit 10.09%
Avg. Invested days 36
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 2.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 09/17/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 3.72M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta -0.19
52 Weeks Range 5.16 - 3756.00
Updated Date 06/29/2025
52 Weeks Range 5.16 - 3756.00
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -3442.8

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -161.01%
Return on Equity (TTM) -694.34%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -5064418
Price to Sales(TTM) -
Enterprise Value -5064418
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -1.01
Shares Outstanding 567456
Shares Floating 428235
Shares Outstanding 567456
Shares Floating 428235
Percent Insiders 8.84
Percent Institutions 1.27

ai summary icon Upturn AI SWOT

GlucoTrack Inc

stock logo

Company Overview

overview logo History and Background

GlucoTrack Inc. is a medical device company focused on developing, manufacturing, and commercializing innovative glucose monitoring solutions for people with diabetes and pre-diabetes. The company's aim is to provide continuous, non-invasive glucose monitoring to improve diabetes management and quality of life.

business area logo Core Business Areas

  • Glucose Monitoring Systems: Develops and markets non-invasive glucose monitoring devices, primarily focusing on the GlucoTrack model.
  • Related Consumables: Sells consumables required for the operation of the GlucoTrack device, such as ear clips.

leadership logo Leadership and Structure

Information regarding leadership and structure specific to GlucoTrack Inc. is limited due to the company being privately held.

Top Products and Market Share

overview logo Key Offerings

  • GlucoTrack Model: A non-invasive glucose monitoring device that uses a clip attached to the earlobe. This device measures glucose levels painlessly and continuously and displays the results on a small handheld device. Market share is minimal compared to traditional blood glucose meters and continuous glucose monitoring (CGM) systems. Competitors include Dexcom (DXCM) and Abbott (ABT) in the CGM market, and various manufacturers of blood glucose meters.

Market Dynamics

industry overview logo Industry Overview

The glucose monitoring market is driven by the increasing prevalence of diabetes globally. There is a growing demand for continuous and non-invasive monitoring solutions, although traditional finger-prick blood glucose meters still dominate.

Positioning

GlucoTrack is positioned as a niche player within the glucose monitoring market, focusing on the non-invasive segment. Its competitive advantage lies in its pain-free measurement approach, but it faces challenges from established CGM players like Dexcom and Abbott, which offer advanced features and proven accuracy.

Total Addressable Market (TAM)

The global diabetes care devices market is projected to reach hundreds of billions of dollars. GlucoTrack targets a subset of this market focused on non-invasive glucose monitoring. The exact percentage of TAM targeted by GlucoTrack is unknown, but their positioning will lead to only a small fraction of the total.

Upturn SWOT Analysis

Strengths

  • Non-invasive glucose measurement technology
  • Potential for improved patient comfort and compliance
  • Addresses the needs of patients averse to needles

Weaknesses

  • Limited clinical validation compared to established CGMs
  • Potentially higher cost per reading compared to traditional methods
  • Accuracy concerns relative to gold-standard glucose measurements

Opportunities

  • Expanding into emerging markets with high diabetes prevalence
  • Developing next-generation non-invasive glucose monitoring devices
  • Partnering with diabetes management platforms and telehealth providers

Threats

  • Intense competition from established CGM manufacturers
  • Regulatory hurdles for new medical devices
  • Changing reimbursement landscape for diabetes care

Competitors and Market Share

competitor logo Key Competitors

  • DXCM
  • ABT

Competitive Landscape

GlucoTrack's main advantage is non-invasive technology. However, major players Dexcom and Abbott dominate the market, so the advantage needs to be more prominent.

Growth Trajectory and Initiatives

Historical Growth: Information on the company's historical growth isn't available because it's private.

Future Projections: Future projections aren't available because it is a private company.

Recent Initiatives: This information isn't available because the company is private.

Summary

GlucoTrack Inc. aims to revolutionize glucose monitoring with non-invasive technology. However, the company faces intense competition from established giants like Dexcom and Abbott in the CGM market. While non-invasive monitoring offers a unique appeal, the company must address concerns of accuracy, cost, and clinical validation. Securing partnerships, expanding market reach, and continuous innovation are crucial for the company's sustainability and growth in the long run.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • Market research reports
  • Industry publications
  • Analyst reports

Disclaimers:

The information provided is based on available public sources and may not be fully comprehensive. Market share estimates are approximate. AI Rating generated based on available data and should not be taken as financial advice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About GlucoTrack Inc

Exchange NASDAQ
Headquaters Rutherford, NJ, United States
IPO Launch date 2013-04-25
CEO, President & Director Mr. Paul V. Goode Ph.D.
Sector Healthcare
Industry Medical Instruments & Supplies
Full time employees 11
Full time employees 11

GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack, a non-invasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain through a small sensor clipped onto the earlobe. It is also developing the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.